These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15623646

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
    Carlo-Stella C, Di Nicola M, Turco MC, Cleris L, Lavazza C, Longoni P, Milanesi M, Magni M, Ammirante M, Leone A, Nagy Z, Gioffrè WR, Formelli F, Gianni AM.
    Cancer Res; 2006 Feb 01; 66(3):1799-808. PubMed ID: 16452241
    [Abstract] [Full Text] [Related]

  • 66. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
    Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I.
    Clin Cancer Res; 2002 Apr 01; 8(4):995-1002. PubMed ID: 11948105
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation.
    Chari RV, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, Shah SA, Liu C, Blättler WA, Goldmacher VS.
    Cancer Res; 1995 Sep 15; 55(18):4079-84. PubMed ID: 7545085
    [Abstract] [Full Text] [Related]

  • 70. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW.
    Clin Cancer Res; 2005 Jul 01; 11(13):4857-66. PubMed ID: 16000584
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice.
    Schwarz MA, Tardelli L, Macosko HD, Sullivan LM, Narula SK, Fine JS.
    Cancer Res; 1995 Sep 01; 55(17):3692-6. PubMed ID: 7641177
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75. In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
    Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH, Kvinnsland Y.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):886-95. PubMed ID: 19679402
    [Abstract] [Full Text] [Related]

  • 76. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
    Damle NK, Frost P.
    Curr Opin Pharmacol; 2003 Aug 01; 3(4):386-90. PubMed ID: 12901947
    [Abstract] [Full Text] [Related]

  • 77. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
    Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J.
    J Pathol; 2005 Jul 01; 206(3):312-9. PubMed ID: 15892171
    [Abstract] [Full Text] [Related]

  • 78. Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice.
    de Kroon JF, Kluin PM, Kluin-Nelemans HC, Willemze R, Falkenburg JH.
    Leukemia; 1994 Aug 01; 8(8):1385-91. PubMed ID: 8057678
    [Abstract] [Full Text] [Related]

  • 79. CD22 as a target for cancer therapy.
    Tu X, LaVallee T, Lechleider R.
    J Exp Ther Oncol; 2011 Aug 01; 9(3):241-8. PubMed ID: 22070056
    [Abstract] [Full Text] [Related]

  • 80. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec 01; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.